Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting

GlobeNewswire April 12, 2021

Medicenna (TSX:MDNA) unveils bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

Brieanna McCutcheon  March 25, 2021

Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

GlobeNewswire March 25, 2021

Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021

GlobeNewswire March 11, 2021

Medicenna Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire March 4, 2021

Medicenna to Present at the Cowen 41st Annual Healthcare Conference

GlobeNewswire February 22, 2021

Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 17, 2021

Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

GlobeNewswire February 12, 2021

Medicenna Establishes At-the-Market Sales Facility

GlobeNewswire December 30, 2020

Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit

GlobeNewswire December 9, 2020

Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme

GlobeNewswire December 2, 2020

Medicenna to Participate in Upcoming December Investor Conferences

GlobeNewswire November 23, 2020

Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting

GlobeNewswire November 18, 2020

Medicenna Reports Second Quarter Fiscal 2021 Financial Results and Operational Highlights

GlobeNewswire November 13, 2020

Medicenna to Present at Upcoming Scientific and Investor Events in November

GlobeNewswire November 2, 2020

Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting

GlobeNewswire October 26, 2020

Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting

GlobeNewswire October 26, 2020

Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting

GlobeNewswire October 19, 2020

Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)

GlobeNewswire October 15, 2020

Dr. Jack Geltosky Elected to Medicenna Board of Directors

GlobeNewswire September 30, 2020